Sirtex launches study to assess SIR-Spheres for HCC
March 22, 2021 -- Radiation oncology firm Sirtex Medical said it has received U.S. Food and Drug Administration approval to begin a multicenter trial to assess its SIR-Spheres yttrium-90 microspheres as a treatment for unresectable advanced hepatocellular carcinoma (HCC). Read More
FDA OK's Boston Scientific's TheraSphere Y-90 microspheres
March 19, 2021 -- The U.S. Food and Drug Administration (FDA) has approved Boston Scientific's TheraSphere yttrium-90 (Y-90) glass microspheres for the treatment of hepatocellular carcinoma. Read More
Akesis radiation therapy system cleared
March 18, 2021 -- Radiation therapy developer Akesis announced it has received 510(k) clearance from the U.S. Food and Drug Administration for its Akesis Galaxy RTi gamma stereotactic radiosurgery system for treating brain diseases and brain cancer. Read More
Radformation releases rad therapy contouring software
March 17, 2021 -- Radiation oncology automation firm Radformation has released AutoContour, an artificial intelligence-based image segmentation software for radiation therapy contouring. Read More
Mevion plans to supply pediatric proton center in China
March 15, 2021 -- Mevion Medical Systems said it has signed a partnership agreement with Children's Hospital of Fudan University in Shanghai and Shanghai Fosun Healthcare to create its first pediatric proton therapy center in China. Read More
NorthStar, IBA expand Tc-99m collaboration
March 8, 2021 -- NorthStar Medical Radioisotopes and proton therapy developer Ion Beam Applications (IBA) are expanding their collaboration in an effort to increase the supply of technetium-99m (Tc-99m) around the world. Read More
RefleXion raises another $40M, mulls Asia strategy
March 5, 2021 -- Radiation therapy equipment developer RefleXion Medical has raised another $40 million in financing, a boost for the advancement of the company's biology-guided radiotherapy for cancer. Read More
Navidea signs deal for $5M in preferred shares
March 5, 2021 -- Radiopharmaceutical developer Navidea Biopharmaceuticals has signed an agreement with the company's largest shareholder for a private placement of up to $5 million in preferred stock. Read More
FDA grants EBTATE investigational new drug status
March 3, 2021 -- Biotechnology developer Molecular Targeting Technologies has received investigational new drug approval from U.S. Food and Drug Administration (FDA) to study EBTATE use in patients with neuroendocrine tumors. Read More
ARTMS gets funds to develop Zr-89 for PET
March 3, 2021 -- Canadian radioisotope developer ARTMS has received $300,000 Canadian from Innovate BC to help develop the radioisotope zirconium-89 (Zr-89) for PET for patients who are eligible for immuno-oncology therapies. Read More
Special Feature
IMV: Imaging boosts precision in radiation therapy

Radiation therapy is a relatively stable market, with procedure volume growing at an average annual rate of 2%. But major technological changes in radiation oncology are brewing under the surface, according to a new report by IMV Medical Information Division. Read more